vs
PennyMac Financial Services, Inc.（PFSI）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是PennyMac Financial Services, Inc.的1.4倍（$772.1M vs $538.0M），PennyMac Financial Services, Inc.净利率更高（1752.5% vs 12.7%，领先1739.7%），PennyMac Financial Services, Inc.同比增速更快（14.4% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-1.7B），过去两年PennyMac Financial Services, Inc.的营收复合增速更高（32.7% vs 9.0%）
PennyMac Financial Services是总部位于美国加利福尼亚州西湖村的住宅抵押贷款企业，核心业务涵盖美国抵押贷款的发放、贷后服务，以及抵押贷款市场相关投资管理。公司下设两家子公司，其中PNMAC资本管理有限公司负责运营旗下的抵押贷款不动产投资信托（REIT）PennyMac Mortgage Investment Trust。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PFSI vs RVTY — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $538.0M | $772.1M |
| 净利润 | $106.8M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 25.0% | 14.5% |
| 净利率 | 1752.5% | 12.7% |
| 营收同比 | 14.4% | 5.9% |
| 净利润同比 | 2.2% | 3.9% |
| 每股收益（稀释后） | $1.97 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $538.0M | $772.1M | ||
| Q3 25 | $632.9M | $698.9M | ||
| Q2 25 | $444.7M | $720.3M | ||
| Q1 25 | $430.9M | $664.8M | ||
| Q4 24 | $470.1M | $729.4M | ||
| Q3 24 | $411.8M | $684.0M | ||
| Q2 24 | $406.1M | $691.7M | ||
| Q1 24 | $305.7M | $649.9M |
| Q4 25 | $106.8M | $98.4M | ||
| Q3 25 | $181.5M | $46.7M | ||
| Q2 25 | $136.5M | $53.9M | ||
| Q1 25 | $76.3M | $42.2M | ||
| Q4 24 | $104.5M | $94.6M | ||
| Q3 24 | $69.4M | $94.4M | ||
| Q2 24 | $98.3M | $55.4M | ||
| Q1 24 | $39.3M | $26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
| Q4 25 | 25.0% | 14.5% | ||
| Q3 25 | 37.3% | 11.7% | ||
| Q2 25 | 17.2% | 12.6% | ||
| Q1 25 | 24.2% | 10.9% | ||
| Q4 24 | 27.5% | 16.3% | ||
| Q3 24 | 22.8% | 14.3% | ||
| Q2 24 | 33.0% | 12.4% | ||
| Q1 24 | 14.4% | 6.8% |
| Q4 25 | 1752.5% | 12.7% | ||
| Q3 25 | 28.7% | 6.7% | ||
| Q2 25 | 30.7% | 7.5% | ||
| Q1 25 | 17.7% | 6.4% | ||
| Q4 24 | 2559.8% | 13.0% | ||
| Q3 24 | 16.8% | 13.8% | ||
| Q2 24 | 24.2% | 8.0% | ||
| Q1 24 | 12.9% | 4.0% |
| Q4 25 | $1.97 | $0.86 | ||
| Q3 25 | $3.37 | $0.40 | ||
| Q2 25 | $2.54 | $0.46 | ||
| Q1 25 | $1.42 | $0.35 | ||
| Q4 24 | $1.95 | $0.77 | ||
| Q3 24 | $1.30 | $0.77 | ||
| Q2 24 | $1.85 | $0.45 | ||
| Q1 24 | $0.74 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $410.0M | $919.9M |
| 总债务越低越好 | $6.2B | — |
| 股东权益账面价值 | $4.3B | $7.3B |
| 总资产 | $29.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.45× | — |
8季度趋势，按日历期对齐
| Q4 25 | $410.0M | $919.9M | ||
| Q3 25 | $62.2M | $931.4M | ||
| Q2 25 | $462.3M | $991.8M | ||
| Q1 25 | $443.4M | $1.1B | ||
| Q4 24 | $420.6M | $1.2B | ||
| Q3 24 | $667.9M | $1.2B | ||
| Q2 24 | $188.8M | $2.0B | ||
| Q1 24 | $69.0K | $1.7B |
| Q4 25 | $6.2B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $5.6B | — | ||
| Q1 25 | $5.8B | — | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $4.9B | — | ||
| Q2 24 | $4.9B | — | ||
| Q1 24 | $4.5B | — |
| Q4 25 | $4.3B | $7.3B | ||
| Q3 25 | $4.2B | $7.4B | ||
| Q2 25 | $4.0B | $7.6B | ||
| Q1 25 | $3.9B | $7.6B | ||
| Q4 24 | $3.8B | $7.7B | ||
| Q3 24 | $3.7B | $7.9B | ||
| Q2 24 | $3.7B | $7.9B | ||
| Q1 24 | $3.6B | $7.8B |
| Q4 25 | $29.4B | $12.2B | ||
| Q3 25 | $25.4B | $12.1B | ||
| Q2 25 | $24.2B | $12.4B | ||
| Q1 25 | $23.9B | $12.4B | ||
| Q4 24 | $26.1B | $12.4B | ||
| Q3 24 | $22.9B | $12.8B | ||
| Q2 24 | $21.6B | $13.4B | ||
| Q1 24 | $19.8B | $13.4B |
| Q4 25 | 1.45× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 1.38× | — | ||
| Q1 25 | 1.48× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.35× | — | ||
| Q1 24 | 1.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7B | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.7B | $161.8M |
| 自由现金流率自由现金流/营收 | -309.3% | 21.0% |
| 资本支出强度资本支出/营收 | 2.2% | 2.6% |
| 现金转化率经营现金流/净利润 | -15.46× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-1.4B | $509.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-1.7B | $182.0M | ||
| Q3 25 | $-697.4M | $138.5M | ||
| Q2 25 | $-131.3M | $134.3M | ||
| Q1 25 | $1.1B | $128.2M | ||
| Q4 24 | $-4.5B | $174.2M | ||
| Q3 24 | $-393.7M | $147.9M | ||
| Q2 24 | $-1.1B | $158.6M | ||
| Q1 24 | $-897.9M | $147.6M |
| Q4 25 | $-1.7B | $161.8M | ||
| Q3 25 | $-699.4M | $120.0M | ||
| Q2 25 | $-132.6M | $115.5M | ||
| Q1 25 | $1.1B | $112.2M | ||
| Q4 24 | $-4.5B | $149.8M | ||
| Q3 24 | $-393.9M | $125.6M | ||
| Q2 24 | $-1.1B | $136.6M | ||
| Q1 24 | $-898.9M | $129.7M |
| Q4 25 | -309.3% | 21.0% | ||
| Q3 25 | -110.5% | 17.2% | ||
| Q2 25 | -29.8% | 16.0% | ||
| Q1 25 | 247.3% | 16.9% | ||
| Q4 24 | -964.7% | 20.5% | ||
| Q3 24 | -95.6% | 18.4% | ||
| Q2 24 | -269.2% | 19.7% | ||
| Q1 24 | -294.1% | 20.0% |
| Q4 25 | 2.2% | 2.6% | ||
| Q3 25 | 0.3% | 2.6% | ||
| Q2 25 | 0.3% | 2.6% | ||
| Q1 25 | 0.1% | 2.4% | ||
| Q4 24 | 0.4% | 3.4% | ||
| Q3 24 | 0.0% | 3.3% | ||
| Q2 24 | 0.1% | 3.2% | ||
| Q1 24 | 0.3% | 2.7% |
| Q4 25 | -15.46× | 1.85× | ||
| Q3 25 | -3.84× | 2.97× | ||
| Q2 25 | -0.96× | 2.49× | ||
| Q1 25 | 13.97× | 3.03× | ||
| Q4 24 | -43.39× | 1.84× | ||
| Q3 24 | -5.68× | 1.57× | ||
| Q2 24 | -11.12× | 2.87× | ||
| Q1 24 | -22.84× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PFSI
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
